Navigation Links
Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
Date:3/5/2009

WALTHAM, Mass., March 5 /PRNewswire/ -- Proteon Therapeutics, Inc., announced today that it has successfully completed a $38 million Series B equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund L.P. This announcement follows the initiation of a Phase 1/2 human clinical study of its lead product, PRT-201, in patients with end stage renal disease undergoing surgery for arteriovenous fistula (AVF) creation. Additionally, Proteon further bolstered its cash reserves by entering into an agreement with Novartis whereby Novartis has been granted an exclusive option to acquire Proteon following the successful completion of a Phase 2 clinical study of PRT-201 with a potential secondary right to a global license under pre-agreed conditions. Including the initial acquisition payment plus potential additional regulatory milestone payments, the deal with Novartis could exceed $550 million.

The Series B financing includes new investors, the MPM Bio IV NVS Strategic Fund L.P. and the Vectis Healthcare & Life Sciences Fund, along with existing investors TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners and several of Proteon's original angel investors. Concurrent with the investment, Proteon also announced the addition of Dr. Steven St. Peter, Managing Director of MPM Capital, to the Proteon Therapeutics Board of Directors.

"Patients with kidney failure endure great suffering and frequent hospitalization due to vascular access complications. If successful, PRT-201 may improve medical outcomes and lower the associated cost of care," said Timothy P. Noyes, President and CEO of Proteon. "We greatly appreciate the continued support of our existing venture and angel investors, and we are excited to welcome MPM and Vectis as new investors." The combination of the Novartis option agreement and the closing of the Series B financing will allow Proteon to develop PRT-201 through Phase 2.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
8. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
9. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
10. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
11. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 “This kit has ... to screen from 0 to 150 ppb,” said Mark Tess, ... a significant benefit to plant owners and USDA-GIPSA inspection agencies ... other commodities. Testing can take place in a matter of ... can the plant test the feed and grain before accepting ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... , , , , Multiporator , , , , , ... Transfection Protocol , Protocol No. 4308 915.041 11/2000 , , ... , , Cell line , ... Transfection with , Plasmid pEGFP-N1 (in bidistilled H 2 O), ...
... , , , , , , Multiporator / Electroporator 2510 , , , ... , Transformation Protocol , Protocol No. 4308 915.531 ... , , , , , , ... , Cell type , ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.525 01/2002 , ... , , , , ... , Cell type , Bacteria, gram positive, ...
Cached Biology Technology:T98G 2Saccharomyces cerevisiae 2Nocardia asteroides 2
(Date:8/29/2014)... stretch them, twist them, fold them: modern materials that ... potential, whether as artificial skin or electronic paper. , ... a challenge but a new way of working with ... a game-changer. , Previous success in the field ... use of precious gold and silver nanowires. , ...
(Date:8/28/2014)... Yale University researchers have identified a handful of bacterial ... as Crohn,s disease and ulcerative colitis, using patients, own ... are published Aug. 28 in the journal Cell ... intestinal microbiota, which plays a critical role in the ... only a small number of bacterial species affect a ...
(Date:8/28/2014)... MD FASEB MARC (Maximizing Access to Research Careers) ... American Society of Human Genetics from October 18 ... are meant to promote the entry of students, post ... of the basic science community and to encourage the ... Human Genetics. This year MARC conferred 16 awards ...
Breaking Biology News(10 mins):Copper shines as flexible conductor 2Yale study identifies possible bacterial drivers of IBD 2
... Valley, NY. (Feb. 13, 2013) Researchers at the ... Medical Research Centre in Warsaw, Poland, have found that ... of immunocompetent research mice when the grafts are injected ... injected into the forceps minor (FM) region. In ...
... plants, far from being passive wallflowers, are "secret gardeners" that ... survival, says a team of scientists from Duke University and ... have long believed that the distribution of plants within a ... different elevations because that,s where conditions like soil aeration and ...
... tissues, diseased organs and tumors inside the body without x-rays ... to the level of atoms? Doctors could make visual diagnoses ... of DNA, watching molecules misfold, or identifying a cancer cell ... associate professor of physics at The City College of New ...
Cached Biology News:Impact of stem cell transplantation location in brain a crucial factor for cell survival 2Marsh plants actively engineer their landscape 2Team creates MRI for the nanoscale 2
... The JNK (c-Jun NH2-terminal kinase) ... three identified MAP kinase pathways in ... response to environmental stress, is associated ... itself, and is implicated in the ...
... knockdown of all human, mouse, and ... Genomewide, predesigned siRNAs for a ... , Ready-to-use, convenient matching solutions for ... Cost-effective RNAi and downstream analysis ...
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... System, which processes two 96-well plates and tracks ... higher level of throughput to the CEQ product ... Coulters new GenomeLab family of products*, also offers ... liquid handers, for increased automation. The CEQ ...
Biology Products: